Search bioRxiv⌕ Search

Biology subjects

Arnott, K.

Publications and source records attributed to Arnott, K..

2 recordsLinked to original sources

Cryo-EM Structure of a Triazole alpha-Conotoxin GI Mimetic Bound to the Muscle-Type Nicotinic Acetylcholine Receptor

Disulfide-rich peptides possess exceptional potency and selectivity but are often limited by the instability and synthetic challenges associated with native disulfide bonds. Here, we report the design, synthesis, pharmacological evaluation, and structural characterisation of triazole-based peptidomimetics of the -GI conotoxin, a selective antagonist of the muscle-type nicotinic acetylcholine receptor (nAChR). A series of 1,4- and 1,5-disubstituted triazole analogues were prepared entirely on resin using CuAAC and RuAAC chemistry to replace the native Cys3/13 disulfide bridge. Functional evaluation against human muscle nAChRs revealed that 1,5-triazole analogues retained low-nanomolar potency, with the lead mimetic exhibiting activity comparable to native -GI. Cryo-electron microscopy of the lead compound bound to the muscle-type nAChR provided the first structure of a disulfide-isostere peptidomimetic in complex with a membrane receptor. The structure demonstrates that the 1,5-triazole reproduces the native peptide fold with high fidelity while contributing receptor-facing interactions not available to the native disulfide bridge. Molecular dynamics simulations further revealed conserved hydration networks and similar conformational sampling between the native peptide and lead mimetic. Together, these findings establish triazoles as effective disulfide surrogates and provide a structural framework for the rational design of stabilised conotoxin therapeutics.

biochemistry↗

Structures of muscle-type nicotinic acetylcholine receptor with α-conotoxins reveal determinants of receptor-subtype specificity

-Conotoxins (-CTX) are disulfide-rich peptide antagonists with exceptional potency and subtype selectivity across nicotinic acetylcholine receptors (nAChRs), making them promising leads for therapeutic development. The molecular basis of their specificity has remained unresolved for decades, limiting rational drug design. Here, we present the first high-resolution cryo-EM structures of full-length muscle-type nAChR bound to three distinct -CTXs, revealing their precise binding modes at both acetylcholine binding sites. Our integrated approach, combining structural biology, pharmacological profiling, and computational hydration mapping, uncovers conserved pharmacophore features, water-mediated interactions, and subunit-specific determinants that govern potency and selectivity. These findings provide a long-sought molecular framework for -conotoxin recognition and inhibition, addressing a critical gap required to realise the full potential of conotoxins as lead compounds in drug discovery.

molecular biology↗